此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Zanidatamab (ZW25) 在 HER2 阳性晚期胆道癌患者中的扩展治疗方案

2025年5月21日 更新者:Jazz Pharmaceuticals

Zanidatamab 用于治疗 HER2 阳性晚期实体瘤的扩展使用

This is an intermediate-size Expanded Access Protocol (EAP) for use of zanidatamab (ZW25) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced biliary tract cancer (BTC) who are not eligible for other zanidatamab clinical trials, and who in the opinion of the treating oncologist, would potentially benefit from treatment with zanidatamab.

研究概览

地位

不再可用

研究类型

扩展访问

扩展访问类型

  • 中型人口

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Candiolo、意大利、10060
        • ICCRS Candiolo
      • Milan、意大利、20133
        • Istituto Nazionale Tumori
      • Milan、意大利、20072
        • Istituto Clinico Humanitas
      • Besançon、法国、25030
        • Jean Minjoz Hospital
      • Marseille、法国、13385
        • Hopital Timone Marseille
      • Pessac、法国、33604
        • Hopital Haut-Leveque - CHU Bordeaux
      • Villejuif、法国、94805
        • Gustave Roussy Cancer Center
    • Arizona
      • Gilbert、Arizona、美国、85234
        • NoCo Banner MD Anderson Cancer Center
    • California
      • Cerritos、California、美国、90603
        • TOI Clinical Research
      • Salinas、California、美国、93901
        • Salinas Valley Memorial Healthcare System
    • Missouri
      • St Louis、Missouri、美国、63110
        • Washington University School of Medicine
      • Harlow、英国、CM20 1QX
        • The Princess Alexandra Hospital NHS Trust (Joanne Kwa, Pharmacist)
      • London、英国、WC1E 6AG
        • UCLH Cancer Institute (Meera Desai, Pharmacist)
      • London、英国、WC1E 6JA
        • HCA Healthcare UK
      • Barcelona、西班牙、08035
        • Vall D'Hebron University Hospital
      • Madrid、西班牙、28041
        • Hospital Universitario 12 de Octubre
      • Madrid、西班牙、28040
        • Fundacion Jimenez Diaz University Hospital - Autonomous University of Madrid

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不适用

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histologically confirmed HER2-positive locally advanced or metastatic biliary tract cancer that has progressed after receipt of available therapies known to confer clinical benefit.
  • Adequate cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) ≥ 50%
  • Adequate organ function
  • Ineligible to participate or has no access to an ongoing zanidatamab or other Zymeworks clinical study (e.g., ZW49 clinical study).
  • Females of childbearing potential and non-sterile males must agree to practice highly effective methods of birth control for the duration of the study and for 12 months after the last dose of study drug. In addition, non-sterile males must avoid sperm donation for the duration of the study and for 12 months after the last dose of study drug.

Exclusion Criteria:

  • Participating in other studies involving investigational drug(s) ≤ 3 weeks before the first dose of zanidatamab.

  • Systemic anti-cancer therapy ≤ 3 weeks before the first dose of zanidatamab.

  • Radiotherapy ≤ 2 weeks of the first dose of zanidatamab

  • The following central nervous system (CNS) brain lesions are excluded from the study:

    • Untreated or unstable brain lesions requiring immediate local therapy or symptomatic CNS metastases.

    • Radiation treatment for CNS metastases within 4 weeks before the first dose of zanidatamab.

    • Known history of or ongoing leptomeningeal disease (LMD). If LMD has been reported radiographically, but is not suspected clinically by the investigator, the patient must be free of neurological symptoms of LMD.

    • The following CNS brain lesions are permitted:

      • Stable brain lesions are permitted if stable, as defined by patients who are off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks at the time of screening.
  • Concurrent uncontrolled or active hepatobiliary disorders or untreated or ongoing complications after laparoscopic procedures or stent placement, including but not limited to active cholangitis, unresolved biliary obstruction, biloma or abscess. Any complications should be resolved within 2 weeks prior to the first dose of zanidatamab.

  • Active hepatitis

  • Infection with human immunodeficiency virus (HIV) with uncontrolled disease.

  • Females who are breastfeeding or pregnant, and females and males planning a pregnancy.

  • History of myocardial infarction or unstable angina within 6 months prior to enrollment, congestive heart failure (NYHA Class 3 or 4), or clinically significant cardiac disease

  • QTc Fridericia (QTcF) > 470 ms assessed within 30 days of screening

  • Acute or chronic uncontrolled pancreatitis or Child-Pugh Class C liver disease

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究注册日期

首次提交

2020年9月30日

首先提交符合 QC 标准的

2020年9月30日

首次发布 (实际的)

2020年10月8日

研究记录更新

最后更新发布 (实际的)

2025年5月25日

上次提交的符合 QC 标准的更新

2025年5月21日

最后验证

2025年5月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • ZWI-ZW25-EAP

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅